Patent Application Titled "Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And Trastuzumab" Published Online (USPTO 20230404908).

A patent application titled "Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And Trastuzumab" has been published online. The application discusses the use of alternating electric fields (TTFields) in combination with the drug trastuzumab to treat HER2-positive breast cancer. TTFields therapy involves applying low-intensity electrical fields to suppress cancer cell proliferation and induce apoptosis. The application describes methods for treating patients by applying an alternating electric field and administering trastuzumab to the target site. The combination of TTFields and trastuzumab has shown enhanced growth inhibition in HER2-positive breast cancer cell lines. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)